Detection of Circulating Tumor Cells from Lung Cancer Patients in the Era of Targeted Therapy : Promises, Drawbacks and Pitfalls

ISSN: 1875-5666 (Online)
ISSN: 1566-5240 (Print)

Volume 17, 10 Issues, 2017

Download PDF Flyer

Current Molecular Medicine

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 47th of 124 in Medicine, Research & Experimental

Submit Abstracts Online Submit Manuscripts Online

David W. Li
College of Medicine
University of Nebraska Medical Center
Omaha, NE

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.912
5 - Year: 3.478

Review Article

Detection of Circulating Tumor Cells from Lung Cancer Patients in the Era of Targeted Therapy : Promises, Drawbacks and Pitfalls

Current Molecular Medicine, 14(4): 440-456.

Author(s): V. Hofman, M. Ilie, E. Long, N. Guibert, E. Selva, K. Washetine, B. Mograbi, J. Mouroux, N. Venissac, J. Reverso-Meinietti, G. Milano, J. Mazieres, C.-H. Marquette, P. Paterlini-Brechot and P Hofman.

Affiliation: Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, 30 Avenue de la voie romaine, 06002 Nice, France.


Interest in biomarkers in the field of thoracic oncology is focused on the search for new robust tests for diagnosis (in particular for screening), prognosis and theragnosis. These biomarkers can be detected in tissues and/or cells, but also in biological fluids, mainly the blood. In this context, there is growing interest in the detection of circulating tumor cells (CTCs) in the blood of lung cancer patients since CTC identification, enumeration and characterization may have a direct impact on diagnosis, prognosis and theragnosis in the daily clinical practice. Many direct and indirect methods have been developed to detect and characterize CTCs in lung cancer patients. However, these different approaches still hold limitations and many of them have demonstrated unequal sensitivity and specificity. Indeed, these methods hold advantages but also certain disadvantages. Therefore, despite the promises, it is currently difficult and premature to apply this methodology to the routine care of lung cancer patients. This situation is the consequence of the analysis of the methodological approaches for the detection and characterization of CTCs and of the results published to date. Finally, the advent of targeted cancer therapies in thoracic oncology has stimulated considerable interest in non-invasive detection of genomic alterations in tumors over time through the analysis of CTCs, an approach that may help clinicians to optimize therapeutic strategies for lung cancer patients. We describe here the main methods for CTC detection, the advantages and limitations of these different approaches and the potential usefulness and value of CTC characterization in the field of thoracic oncology.


Cancer screening, circulating tumor cells, diagnosis, lung cancer, personalized medicine, prognosis, targeted therapy.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 14
Issue Number: 4
First Page: 440
Last Page: 456
Page Count: 17
DOI: 10.2174/1566524014666140414205455
Price: $58
Global Biotechnology Congress 2017Drug Discovery and Therapy World Congress 2017

Related Journals

Related eBooks

Webmaster Contact: Copyright © 2017 Bentham Science